Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Total Tests Reported by Quarter
Total Tests Reported — Resulting in a Customer Report (tests)
Natera Total Tests Reported: 985,500.00 tests in Q2 2026, up 21.2% from a year earlier. That is the highest of the 20 quarters on record here.
Where the Q2 2026 figure comes from
“During the three months ended June 30, 2026, total reported units were approximately 985,500, comprised of approximately 972,000 tests reported in our laboratories. Comparatively, during the three months ended June 30, 2025, total reported units were approximately 812,900, which is comprised of approximately 799,900 tests reported in our laboratory.”
Source: Form 10-Q (2026-06-30) ↗
Total tests processed that successfully generated a clinical report delivered to the ordering provider or laboratory partner.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Tests Reported — Resulting in a Customer Report (tests) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 985,500.00 | +21.2% | Form 10-Q (2026-06-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 931,600.00 | +15.8% | Form 10-Q (2026-03-31) ↗ |
| Q4 2025 | Dec 31, 2025 | 892,400.00 | +15.6% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 832,900.00 | +11.0% | Form 10-Q (2025-09-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 812,900.00 | +12.1% | Form 10-Q (2026-06-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 804,800.00 | +18.5% | Form 10-Q (2026-03-31) ↗ |
| Q4 2024 | Dec 31, 2024 | 771,700.00 | +24.5% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 750,100.00 | +27.1% | Form 10-Q (2025-09-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 725,200.00 | +21.9% | Form 10-Q (2025-06-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 679,400.00 | +16.5% | Form 8-K Ex 99.1 (2025-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 619,800.00 | +19.4% | Form 8-K Ex 99.1 (2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 590,000.00 | – | Form 10-Q (2024-09-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 594,900.00 | – | Form 8-K Ex 99.1 (2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 583,400.00 | – | Form 8-K Ex 99.1 (2024-05-09) ↗ |
| Q4 2022 | Dec 31, 2022 | 519,200.00 | +26.4% | Form 8-K Ex 99.1 (2024-02-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 410,900.00 | – | Form 8-K Ex 99.1 (2023-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 238,600.00 | +25.8% | Form 10-Q (2020-09-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 220,100.00 | +17.3% | Form 10-Q (2020-06-30) ↗ |
| Q3 2019 | Sep 30, 2019 | 189,600.00 | – | Form 10-Q (2020-09-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 187,600.00 | – | Form 10-Q (2020-06-30) ↗ |
Breakdown
What makes up total Tests Reported
Cite this data
StockData. (2026). Natera Total Tests Reported, quarterly Q2 2019–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-tests-reported-total
See every metric in the Natera KPI table. Data updated Nov 2, 2026.